CAR-T	Chimeric antigen receptor T cells
CM	Cutaneous melanoma
CR	Complete response
DC	Dendritic cell
DCR	Disease control rates
DCR	Disease control rate
GM-CSF	Granulocyte–macrophage colony-stimulating factor
HAVCR2	Hepatitis A virus cellular receptor 2
ICI	Immune checkpoint inhibitor
IDO	Indoleamine 2,3-dioxygenase
IFN-β	Interferon-beta
IFN-γ	Interferon-gamma
IHP	Isolated hepatic perfusion
IL-12	Interleukin-12
IL-2	Interleukin-2
LAG-3	Lymphocyte activation gene-3
MDSCs	Myeloid-derived suppressor cells
mOS	Median overall survival
mPFS	Median progression-free survival
mUM	Metastatic uveal melanoma
NSCLC	Non-small-cell lung cancer
ORR	Objective response rates
ORR	Objective response rate
OS	Overall survival
OSR	Overall survival rates
PD	Progressive disease
PFS	Progression-free survival
PHP	Percutaneous hepatic perfusion
PR	Partial response
RECIST	Response Evaluation Criteria in Solid Tumors
SD	Stable disease
SIRT	Selective internal radiation therapy
TACE	Transarterial chemoembolization
TCR	T cell receptor
TCR-T	TCR-engineered T cells
TDO	Tryptophan 2,3-dioxygenase
TIGIT	T cell immunoreceptor with Ig and ITIM domains
TIL	Tumor-infiltrating lymphocyte
TIM-3	Mucin-domain containing-3
TLR9	Toll-like receptor 9
Tregs	Regulatory T cells
TYRP1	Tyrosinase-related protein 1
UM	Uveal melanoma
VEGF	Vascular endothelial growth factor
VSV	Vesicular stomatitis virus